Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced that it has closed its private placement of unsecured convertible notes for aggregate gross proceeds of AUD$3,215,000, which represents an oversubscription of AUD$215,000 … Continue reading InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Closing of Oversubscribed Private Placement